A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was: what dose of tranexamic acid is most effective and safe for adult patients undergoing cardiac surgery? Altogether 586 papers were found using the reported search, of which 12 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. Current evidence shows clinical benefit of using high-dose tranexamic acid (>80 mg/kg total dose) as opposed to low-dose tranexamic acid (<50 mg/kg total dose) in cardiac surgery with cardiopulmonary bypass. Evidence from a large randomized controlled trial shows that patients receiving high-dose tranexamic acid lose less blood postoperatively than patients receiving low-dose tranexamic acid (590 vs 820 ml, P = 0.01). Patients receiving high-dose tranexamic acid also require fewer units of blood product transfusion (2.5 units vs 4.1 units; P = 0.02) and are less likely to undergo repeat surgery to achieve haemostasis. This effect is larger in those who are at high risk of bleeding. Several prospective studies comparing doses found no difference in clinical outcomes between high-and low-dose regimens, but excluded patients at high risk of bleeding. However, data from numerous observational studies demonstrate that tranexamic acid use is associated with an increased risk of postoperative seizure; one analysis showed tranexamic acid use to be a very strong independent predictor (odds ratio = 14.3, P < 0.001). There is also evidence that this risk of seizure is dose-dependent, with the greatest risk at higher doses of tranexamic acid. We conclude that, in general, patients with a high risk of bleeding should receive high-dose tranexamic acid, while those at low risk of bleeding should receive low-dose tranexamic acid with consideration given to potential dose-related seizure risk. We recommend the regimens of high-dose (30 mg kg −1 bolus + 16 mg kg −1 h −1 + 2 mg kg −1 priming) and low-dose (10 mg kg −1 bolus + 1 mg kg −1 h −1 + 1 mg kg −1 priming) tranexamic acid, as these are well established in terms of safety profile and have the strongest evidence for efficacy.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS [1] . 
THREE-PART QUESTION

CLINICAL SCENARIO
Mr AB is to undergo coronary artery bypass grafting with cardiopulmonary bypass (CPB), the indication for which is unstable angina. He has no other significant past medical history or comorbidities. At perioperative assessment, he is found to have mild normocytic anaemia, haemoglobin 11.2 g/dl and mean corpuscular volume 86 fl, increasing the importance of minimizing blood loss. You are aware that various dosing regimens for tranexamic acid (TA) administration exist, but are unsure which provides the best outcome in cardiac surgery. To optimize management, you perform a literature review of the best available evidence. Seizure within 24 h of CPB OR for seizure in patients receiving >100 mg kg −1 TA = 2.6 (P < 0.0001) Pre-existing non-acute discrete lesion on brain imaging in 30% of early seizure patients
SEARCH STRATEGY
Continued
SEARCH OUTCOME
A total of 586 papers were found using the reported search. From these, 12 papers were identified that provided the best evidence to answer the question. These are presented in Table 1 .
RESULTS
Sigaut et al.
[2] demonstrated differences in postoperative blood loss and incidence of repeat surgery between high (30 mg kg bolus + 1 mg kg −1 h −1 + 1 mg kg −1 priming) dose TA regimens in 569 adult patients on CPB for cardiac surgery. Mean blood loss in the low-dose group was 820 ml during day 1, compared with 590 ml for the high-dose group (P = 0.01). While statistically significant, the mean difference (230 ml) is small. Repeat surgery to achieve haemostasis was performed in 6.2% of low-dose patients compared with 2.5% of high-dose (P = 0.03). Subgroup analysis showed the greatest reduction in bleeding and repeat surgery was observed in patients at high transfusion risk. No differences in 7-day transfusion incidence or 28-day mortality were observed, although the amount of blood products transfused was lower in the high-dose TA group (2.5 units) than the low-dose group (4.1 units) (P = 0.02).
Waldow et al. [3] conducted a larger study (n = 1182) in on-pump cardiac surgery patients and detected no statistically significant differences in blood loss, 30-day mortality, myocardial infarction or stroke between patients receiving low (1 g priming dose), moderate (5 g priming dose) or high-dose TA (3 g priming dose plus weight-adjusted infusion).
Du et al. [4] found no difference between clinical outcomes with high (30 mg kg −1 bolus + 16 mg kg −1 h −1 + 2 mg kg −1 priming dose) and low (10 mg kg −1 bolus + 2 mg kg −1 h −1 + 40 mg priming dose) dose TA in 175 patients undergoing valve surgery. Rates of blood loss, red blood cell (RBC) transfusion and fresh frozen plasma (FFP) transfusion were similar between groups. This study, however, excluded patients with renal and hepatic failure (and consequently at a higher risk of bleeding), the group for whom the greatest differences in blood loss were detected in Sigaut et al.'s study [2] .
Armellin et al. [5] concluded that blood loss and transfusion rates of both RBCs and FFP were similar in 250 patients randomized to receive either high (30 mg kg −1 bolus + 30 mg kg −1 priming dose) or low (15 mg kg −1 bolus + 1 mg kg
) dose TA during coronary revascularization.
Faraoni et al. [6] demonstrated no difference in clinical outcomes or fibrinolysis between high (30 mg kg −1 bolus + 16 mg kg
) and low (5 mg kg −1 bolus + 5 mg kg −1 h −1 ) dose TA. With 33 patients included, this small pilot study may have been inadequately powered to detect true differences.
Retrospective multivariate regression analyses by Koster et al. [7] , Manji et al. [8] and Sharma et al. [9] demonstrate that TA use is associated with increased risk of postoperative seizure in patients undergoing cardiac surgery with CPB [odds ratio (OR) = 1.703, P = 0.045; OR = 7.4, P < 0.001 and OR = 14.3, P < 0.0001, respectively]. Subgroup analysis performed by Koster et al. [7] showed that this increased risk of seizure with TA was statistically significant for open heart surgery and not for coronary artery bypass graft. Koster et al. [7] also found that TA use was associated with increased in-hospital mortality (OR = 1.89, P = 0.005). The TA group were higher risk in terms of factors including age and presence of pulmonary disease; the authors used a propensity score adjustment in their analysis.
Observational data demonstrate that higher doses of TA are associated with higher seizure risk than low-dose TA. Sharma et al. [9] observed less risk of seizure in patients receiving low-dose (50 mg kg −1 ) than those receiving high-dose TA (>80 mg kg −1 ) (0.3 vs 2.6% P < 0.0001). Kalavrouziotis et al. [10] , using a similar multivariate regression analysis approach, found that >100 mg kg −1 total TA dose was an independent predictor of seizure within 24 h of surgery (OR = 2.6 P < 0.0001). Evidence of pre-existing non-acute discrete lesions on brain imaging was present in 30% of these seizure patients.
No prospective trials have demonstrated an association between TA and increased seizure risk. As a result, no causal relationship can be inferred from available data.
Pharmacokinetic studies show that high-dose TA is not required to achieve adequate inhibition of fibrinolysis. Sharma et al. [11] analysed plasma TA concentrations of 8 patients undergoing elective cardiac surgery with CPB and high-dose TA (30 mg kg −1 bolus + 16 mg kg −1 h −1 infusion + 2 mg kg −1 priming dose). The authors found that actual plasma levels of TA were significantly higher than expected, based on previous modelling approaches [12, 13] , and that 100% inhibition could be achieved at lower TA doses.
CLINICAL BOTTOM LINE
Patients at high risk of bleeding should receive high-dose TA (30 mg kg −1 bolus + 16 mg kg −1 h −1 + 2 mg kg −1 priming), while those at low risk of bleeding should receive low-dose TA (10 mg kg −1 bolus + 1 mg kg −1 h −1 + 1 mg kg −1 priming) with consideration given to potential dose-related seizure risk.
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